[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,861
Citations 0
Editorial
May 17, 2016

Toward a Patient-Centered Value Framework in Oncology

Author Affiliations
  • 1Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill
  • 2Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill
  • 3Associate Editor, JAMA
JAMA. 2016;315(19):2073-2074. doi:10.1001/jama.2016.4637

Cancer drugs are toxic and expensive. Their benefits are often difficult to measure, vary substantially between patients, and too often are quite modest in improving outcomes. Multiple approaches have been developed recently to quantify and combine these treatment characteristics (harms, costs, and benefits) into composite “value” metrics that enable crosstreatment comparisons, formulary prioritization, and assessments of whether pricing is reasonable.

In their Viewpoint in this issue of JAMA, Chandra and colleagues1 compare 5 such frameworks for assessing the value of cancer drugs: the American Society of Clinical Oncology “Value Framework” (ASCO)2; the European Society for Medical Oncology “Magnitude of Clinical Benefit Scale” (ESMO)3; the Institute for Clinical and Economic Review “Value Assessment Framework” (ICER)4; the Memorial Sloan Kettering Cancer Center “Drug Abacus” (MSK)5; and the National Comprehensive Cancer Network “Evidence Blocks” (NCCN).6

First Page Preview View Large
First page PDF preview
First page PDF preview
×